does glp 1 cause anxiety An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders GLP-1 receptor agonists show promise

Asia-Pacific is the fastest-growing regional GLP-1 drug market at 22.6% CAGR , driven by rapidly rising obesity prevalence China now reports 18.6% adult obesity prevalence up from 7.1% in 2000 combined with expanding private health insurance and regulatory approvals

Recent data from insurance claims indicates that 30% of patients stop treatment within a month, well before any clinically meaningful results could be achieved

Regular monitoring and personalized care can help guide these decisions

Dan Skovronsky, Eli Lillys chief scientific officer, told NBCs Stephanie Gosk in an exclusive interview that aired on TODAY in April

The process for approval was very smooth and my package arrived timely